Research programme: protein therapeutics - Affibody

Drug Profile

Research programme: protein therapeutics - Affibody

Alternative Names: CAIX - Affibody; HER3 - Affibody

Latest Information Update: 23 Apr 2012

Price : $50

At a glance

  • Originator Affibody
  • Class Proteins
  • Mechanism of Action Carbonic anhydrase inhibitors; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Cancer

Most Recent Events

  • 23 Apr 2012 Research is ongoing in Sweden
  • 12 Oct 2005 Early research in Breast cancer in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top